Inactive Instrument

20/20 Global, Inc. Other OTC

Equities

TWGL

US90138D1072

20/20 Global, Inc. Announces Appointment of Ben Kaplan as CEO

January 20, 2021 at 01:30 pm

20/20 Global, Inc. announced appointment of Ben Kaplan who is Chairman and CEO of Ehave, Inc. as its CEO.

Latest news about 20/20 Global, Inc.

Mycotopia Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Mycotopia Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-23	CI
Mycotopia Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Mycotopia Therapies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/08/23	CI
Mycotopia Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	14/07/23	CI
Mycotopia Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
Mycotopia Therapies, Inc. Auditor Raises 'Going Concern' Doubt	29/03/23	CI
Ei.Ventures, Inc. cancelled the acquisition of Mycotopia Therapies Inc. from EHAVE, Inc. (OTCPK:EHVV.F) and others in a reverse merger transaction.	15/02/23	CI
Mycotopia Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Mycotopia Therapies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/08/22	CI
Mycotopia Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	23/05/22	CI
Ehave Announces Mycotopia Therapies Reaches Definitive Agreement on Triangular Merger with Ei.Ventures to Form PSLY.com to List on NASDAQ	23/05/22	CI
Mycotopia Therapies Partners with Public Policy Specialist PsychedelicsEUROPE to Explore Opportunities in the European Market	02/05/22	CI
Mycotopia Therapies Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	14/04/22	CI
Mycotopia Therapies, Inc. Auditor Raises 'Going Concern' Doubt	13/04/22	CI
Mycotopia Therapies, Inc. Expands Presence In The Registered Mushroom Sector With HAVN Life Sciences Inc	17/03/22	CI
Ei.Ventures, Inc. entered into a letter of interest to acquire Mycotopia Therapies Inc. in a reverse merger transaction for $360 million.	06/12/21	CI
Mycotopia Therapies and Agile Pharmaceutical Solutions Plan to Conduct Oversight and Development of the Tablet in Jamaica and Explore the Possibility of Partnering with Havn Life Sciences in Jamaica	17/11/21	CI
Mycotopia Therapies Inc. Appoints Dr. Saphire Longmore as Chief Medical Officer of Caribbean Affairs	10/11/21	CI
Mycotopia Therapies Inc. has Changed its Ticker to MYCO from TPIA	04/05/21	CI
20/20 Global, Inc. Announces Management Resignations	30/03/21	CI
Mycotopia Therapies (20/20 Global, Inc.) Announces Joint Venture with Biomedican to Establish Biosynthetic Compound Subsidiary Known as PsyBioMed	08/02/21	CI
Mycotopia Therapies Inc. completed the acquisition of 20/20 Global, Inc. in a reverse merger transaction.	18/01/21	CI
Mycotopia Therapies agreed to acquire 20/20 Global, Inc. for $0.35 million in a reverse merger transaction.	27/12/20	CI

Chart 20/20 Global, Inc.

Duration

Period

More charts

Company Profile

Sector

More about the company